Doctors urged to cut medicine prescription waste
Doctors have been urged to change how they prescribe medicines to stop
Doctors have been urged to change how they prescribe medicines to stop
Researchers from the University of Dundee have developed a new strategy for prescribing antibiotics that could reduce patient harm and help combat the rise in antibiotic resistance.
A new study found that a new prescribing protocol could significant reduce potential misuse of antibiotics.
The research followed over 500 patients with lower respiratory tract infections during the course of one year. The new prescribing protocol included automatic stop dates, with time limits on prescriptions depending on the severity of an infection, coupled with support from pharmacists to ensure that antibiotics were issued with stop dates that were clearly visible for patients.
During the first half of the 12-month trial, researchers monitored patients’ current duration of antibiotic use. In the second half, patients receiving antibiotics followed the new prescribing strategy. During both phases of this study, researchers monitored antibiotic side-effects, including new symptoms occurring during the period of antibiotic exposure that were potentially caused by the antibiotics. They also monitored patients’ length of stay in hospital and death rates.
The study found that when the new protocol was followed, there was a near 20 per cent reduction in antibiotic use and an associated 40 per cent reduction in antibiotic-related side-effects.
Dr Matthew Lloyd, lead author from the University’s School of Medicine, said, ‘The threat from growing resistance to antibiotics is increasing, which is in part attributable to inappropriately lengthy courses of antibiotics.
‘Our study aimed to implement a simple system for preventing patients taking antibiotics for longer than they should. The results were promising and found that through prescribing automatic stop dates and working with our multidisciplinary colleagues, we can help prevent this problem and reduce patient harm.’ University of Dundee
University of Utah electrical engineers have developed a network of wireless sensors that can detect a person falling. This monitoring technology could be linked to a service that would call emergency help for the elderly without requiring them to wear monitoring devices. For people age 65 and older, falling is a leading cause of injury and death. Most fall-detection devices monitor a person
Research jointly conducted by investigators at Institut Gustave Roussy, Inserm, Institut Pasteur and INRA (French National Agronomic Research Institute) has led to a rather surprising discovery on the manner in which cancer chemotherapy treatments act more effectively with the help of the intestinal flora (also known as the intestinal microbiota). Indeed, the researchers have just shown that the efficacy of one of the molecules most often used in chemotherapy relies to an extent on its capacity to mobilise certain bacteria from the intestinal flora toward the bloodstream and lymph nodes. Once inside the lymph nodes, these bacteria stimulate fresh immune defences that then enhance the body
Although some studies have portrayed tight blood sugar control as a potential means of lowering infection rates in critically ill adults, a new study
The Journal of Hospital Infection (JHI) has just released the awaited epic3 guidelines on infection prevention and control for a range of healthcare professionals. They are freely available online on ScienceDirect and on the journal’s website.
The guidelines were commissioned by the UK Department of Health and have been developed after a systematic and expert review of all the available scientific evidence. They update and supersede the previous guidelines on this topic published in 2007.
Infection prevention and control came to the public awareness after the rise of MRSA and C. difficile in particular in the middle of the last decade. Since the publication of the 2007 guidelines, more resistant organisms have emerged, some of which are now almost untreatable by antimicrobials. This is actually no great surprise, as the development of resistance to antibiotics is an inevitable consequence of evolution- microbes have been producing chemical weapons to destroy each other since the dawn of life on earth. Resistance means survival. There are no really new antimicrobial agents under development, and for the first time, we are facing a world where more bacterial infections may be untreatable. Contrary to popular belief, we always had several treatment options available to treat MRSA.
Microbiologist Dr Jenny Child, Editor in Chief of The Journal of Hospital Infection, said ‘It is difficult to stop the rise of increasingly resistant organisms. What we can do however is prevent them spreading between patients and becoming established among the resident microbial flora- the bacterial population in our hospitals. Infection prevention and control has never been more important than it is now.’
It is no coincidence that the very first of the seven key action points outlined in the UK 5-year Antimicrobial Resistance Strategy 2013-1018, produced earlier this year by the DoH and DEFRA, is about improving infection prevention and control.
In her Forward to the epic3 Guidelines, which will accompany the January 2014 printed issue of The Journal of Hospital Infection, Professor Dame Sally Davies, NHS England’s Chief Medical Officer, said, ‘In March 2013, my Annual Report on ‘Infection and the rise of antimicrobial resistance’ highlighted the need for healthcare professionals to understand and put into practice the principles of infection prevention and control in order to improve patient outcomes. These updated guidelines underpin and provide the knowledge base to inform this understanding’.
‘The guidelines provide the evidence base for many elements of clinical practice that are essential in minimizing the spread of antimicrobial-resistant organisms, and maintaining high standards of infection prevention and control that can be adapted for use locally by all healthcare practitioners. The principles set out in these guidelines also provide the evidence base to support elements of the implementation of the 5-year UK Antimicrobial Resistance Strategy,’ Davies added.
EurekAlert
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Dr. Edward Garon, director of thoracic oncology at UCLA’s Jonsson Comprehensive Cancer Center, presented the preliminary results of a Phase 1B study of the new drug, called MK-3475, on Oct. 29 at the World Conference on Lung Cancer in Sydney, Australia.
The detailed interim data on safety and activity came from a cohort of 38 patients with non-small cell lung cancer who were treated previously for the disease without positive results. For the study, the patients received MK-3475 every three weeks.
Among the participants, 24 percent responded to the drug, with their tumours shrinking, and the median overall survival rate was 51 weeks. For those who responded, the median response duration
Certain pediatric surgeries carry such low risk of serious blood loss that clinicians can safely forgo expensive blood typing and blood stocking before such procedures, suggest the results of a small study by researchers at the Johns Hopkins Children
Rice University nanotechnology researchers have unveiled a solar-powered sterilization system that could be a boon for more than 2.5 billion people who lack adequate sanitation. The
Improving vaccination rates against the human papillomavirus (HPV) in boys aged 11 to 21 is key to protecting both men and women, says new research from University of Toronto Professor Peter A. Newman from the Factor-Inwentash Faculty of Social Work.
HPV has been linked to anal, penile and certain types of throat cancers in men. Since the virus is also responsible for various cancers in women, vaccinating boys will play a crucial role in reducing cancer rates across the sexes.
April 2024
The medical devices information portal connecting healthcare professionals to global vendors
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy